Financial
FY2025 revenue $176.0m (+40.0%); operating margin -36.4%; net loss $116.8m.
No debt; $280.2m cash.
HeartFlow
HQ United States · North America
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Weak
Customer rating
No reviews yet
Financial health
Band: WeakListed: HTFL
FY2025 revenue $176.0m (+40.0%); operating margin -36.4%; net loss $116.8m.
No debt; $280.2m cash.
Source: official results release · Year ended 2025-12-31 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | US$176m | +40.0% | -US$64.1m | -US$116.8m | HeartFlow |
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
Apr 2026: HeartFlow sued rival Cleerly in US federal court (E.D. Texas), alleging patent infringement and misuse of its confidential information; Cleerly denies the claims. Jul 2025: HeartFlow filed for a US IPO.
Cyber & information governance
No data breaches, cyber incidents or regulator action involving HeartFlow found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
No product recalls, FDA warning letters or safety notices involving HeartFlow found in HSH's search of the last 24 months.
Contract performance
No notable contract disputes, terminations or troubled implementations involving HeartFlow found in HSH's search of the last 24 months.
Competitors
No competitors linked yet.